ABSTRACT Background: The use of intravenous lipid emulsions in preterm infants has been limited by concerns regarding impaired lipid tolerance. As a result, the time of initiation of parenteral lipid infusion to very-low-birth-weight (VLBW) infants varies widely among different neonatal intensive care units. However, lipids provide energy for protein synthesis and supply essential fatty acids that are necessary for central nervous system development. Objective: The objective was to summarize the effects of initiation of lipids within the first 2 d of life and the effects of different lipid compositions on growth and morbidities in VLBW infants. Design: A systematic review and meta-analysis of publications identified in a search of PubMed, EMBASE, and Cochrane databases was undertaken. Randomized controlled studies were eligible if information on growth was available. Results: The search yielded 14 studies. No differences were observed in growth or morbidity with early lipid initiation. We found a weak favorable association of non-purely soybean-based emulsions with the incidence of sepsis (RR: 0.75; 95% CI: 0.56, 1.00). Conclusions: The initiation of lipids within the first 2 d of life in VLBW infants appears to be safe and well tolerated; however, beneficial effects on growth could not be shown for this treatment nor for the type of lipid emulsion. Emulsions that are not purely soybean oil-based might be associated with a lower incidence of sepsis. Large-scale randomized controlled trials in preterm infants are warranted to determine whether early initiation of lipids and lipid emulsions that are not purely soybean oil-based results in improved long-term outcomes.
INTRODUCTION
Postnatal growth failure is one of the most commonly observed morbidities in very-low-birth-weight (VLBW) 4 infants (1-3). Proteins are the driving force for growth, and protein synthesis is an energy-demanding process. Therefore, sufficient energy should be administered to optimize this process. Lipids are an attractive energy source because of their high energy density and their supply of essential n26 and n23 fatty acids necessary for central nervous system development. An inadequate exogenous supply of essential fatty acids (EFAs) and/or their derivatized long-chain PUFAs during the critical periods of rapid brain and retinal growth may lead to long-term impairment of neurodevelopment and visual function (4) . However, the use of intravenous lipid emulsions in preterm infants has been limited by concerns regarding impaired lipid tolerance, including increased albuminbound bilirubin displacement, impairment of oxygenation, and bronchopulmonary dysplasia (BPD). Among different neonatal intensive care units, the time of initiation of parenteral lipid emulsions to preterm infants varies widely (5-7), even though postponing lipid administration during this critical period of organ development may lead to insufficient energy supply for protein synthesis and a shortage of EFAs for normal brain development. A Cochrane meta-analysis compared the initiation of lipids in preterm infants in 5 studies before and after 5 d of life. The primary outcomes of growth, death, and BPD were not different between "early" (,5 d) and "not early" (.5 d) initiation of lipids (8) . In 2005 the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition Committee on Nutrition stated that in newborn infants who cannot receive sufficient enteral feeding, administration of intravenous lipid emulsions should be started no later than on the third day of life but may be started on the first day of life (9) . Therefore, the first objective of this systematic review and meta-analysis was to identify the most suitable timing for early introduction of parenteral lipids, and our determination was that initiation is best within the first 2 d of life. The European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines and available studies that were published after the Cochrane metaanalysis support our hypothesis.
Since the 1960s, safe commercial parenteral lipid emulsions have been widely used. Purely soybean oil-based emulsions were the first lipid emulsions available for parenteral use and are still the most often used parenteral lipid source (10) . However, in several newer emulsions, soybean oil is combined with other lipid sources, such as coconut oil [providing medium-chain triacylglycerols (MCTs)], olive oil, and/or fish oil. Each type of lipid has different characteristics and potential benefits or disadvantages. Several of these recently developed mixed-lipid emulsions have been shown in small studies to improve tolerance and short-and long-term outcomes, such as a lower incidence of parenteral nutrition-associated liver disease (PNALD) (11, 12) . Nevertheless, it is not clear which lipid composition is most beneficial for a premature infant. Therefore, the second objective of the present systematic review and meta-analysis was to identify the most suitable lipid composition for parenteral nutrition in VLBW infants.
METHODS
The requirements of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement were followed (13) .
Search strategy for identification of studies
A PubMed (http://www.ncbi.nlm.nih.gov/pubmed), EMBASE (http://www.embase.com), and Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, www. thecochranelibrary.com, Issue 8, 2011) search up to 23 February 2012 was conducted with the use of the following key terms (words in the title or abstract of the manuscript): "lipid," "fat," "fatty acid," "oil," "parenteral," "intravenous," and "infusion"; the lipid type2related terms "soy," "soybean," "medium chain triacylglycerol," "olive," "fish," "n26," "n23," and "emulsion"; and the population-related terms "very low birth weight," "preterm," and "neonate." The searches were limited to human studies. No language restriction was applied in the search. The complete PubMed, EMBASE, and Cochrane searches are shown elsewhere (see the Online Supplemental Material under "Supplemental data" in the online issue). We (HV and MABV) performed a manual search of reference lists of all relevant studies on this topic. The citations with abstracts were uploaded into a reference database (EndNote ·3; Thomson Reuters) and checked for duplicates.
Data collection
HV and MABV independently selected the studies, and discrepancies were resolved by consensus. Studies were included if they met all of the following criteria: parallel-group randomized controlled trial (RCT) study design, preterm infants weighing ,1500 g admitted to a neonatal intensive care unit who needed parenteral nutrition and who received any type of parenteral lipid emulsion within the first days of life, and growth included as an outcome measure. No restriction on the dose of lipid infusion was applied. Cohort studies, case series, case reports, and trials studying only infants with congenital abnormalities were excluded.
Data extraction and management
Both reviewers (HVand MABV) read the selected articles. HV extracted, assessed, and coded all data for each study by using a form that was designed specifically for this review. Any SEM was replaced by the corresponding SD. For each study, HV entered final data into RevMan (RevMan version 5.1, 2011; Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration). MABV checked the extraction process and entered data. At each stage, any disagreement was resolved by discussion. The extracted study data consisted of the following: 1) general study information, including title, first author, journal, and year of publication; 2) study design and characteristics of study participants [including number, gestational age (wk), birth weight (g), and specific inclusion and exclusion criteria per study]; 3) type of intervention and control treatment (including duration, start of lipid administration, type of lipid, starting and final dose of administered lipids, and cointerventions in addition to lipids); and 4) outcome measures.
Outcome measures were divided into the primary outcome rate of weight gain and 16 secondary outcomes as follows: 1) death; 2) incidence of BPD defined as oxygen therapy or any form of respiratory support at 36 wk postmenstrual age; 3) duration of respiratory support (d); 4) supplemental oxygen (d); 5) incidence of necrotizing enterocolitis (NEC) stage !2 on Bell's staging system (14); 6) retinopathy of prematurity (ROP), defined as any stage of ROP during the weeks after birth observed by direct or indirect ophthalmoscope, as defined by the International Classification of Retinopathy of Prematurity classification (15); 7) significant patent ductus arteriosus (PDA) diagnosed clinically or by echocardiograph as needing treatment, either conservatively by fluid restriction, diuretics, indomethacin/ibuprofen or by surgery; 8) sepsis, defined as a positive blood culture; 9) intraventricular hemorrhage (IVH), all grades, and severe IVH (grades 3 and 4) of Papile classification (16); 10) significant jaundice, necessitating phototherapy or exchange transfusion; 11) PNALD defined as conjugated bilirubin .2 mg/dL or 34.2 lmol/L, with or without increased liver enzymes in the absence of other causes (17) 
Assessment of study quality
The level of evidence of each article was established following the Oxford Centre for Evidence-Based Medicine Level of Evidence scale (21) . The quality of the RCTs was assessed by 2 authors (HV and MABV) by using the Jadad criteria (22) (0-5-point rating scale, with 5 as the maximum score).
Data analysis
Analyses were performed by using Review Manager software (RevMan version 5.1, 2011; Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration). Two-sided P values 0.05 were considered to be significant.
Measures of treatment effect
The first comparison of this study was early ( 2 d) compared with late (.2 d) initiation of lipids in preterm infants. A second comparison was performed to compare parenteral purely soybeanbased emulsions with any other type of lipid emulsion.
For both comparisons, the primary and 16 secondary outcomes were compared. To analyze treatment effect and calculate a pooled mean of outcomes reported in !2 studies, the Mantel-Haenszel method was used for categorical outcomes, and the inverse variance method was used for continuous outcomes. The data from each study were summarized in forest plots, and summary estimates with 95% CIs were calculated. For outcomes measured on a continuous scale, the weighted mean difference with a 95% CI was used. In assessing the treatment effects for categorical outcomes, the RR with a 95% CI was used.
Assessment of heterogeneity
For all outcome measures, we assessed statistical heterogeneity by calculating the Q-statistic (P , 0.05 considered as heterogeneous) and the I 2 statistic (I 2 .50% was considered heterogeneous) to assess in what amount the data from the included studies were heterogeneous (23) .
Assessment of reporting biases
To detect publication bias, a funnel plot was constructed. However, there were an insufficient number of studies to permit proper evaluation of publication bias and to evaluate potential asymmetry of the funnel plot by Begg and Egger tests.
Sensitivity analysis
In cases of low study quality, great variability in study protocols (eg, lipid dose, duration of lipid administration), or other arbitrary findings, a sensitivity analysis was performed by removing this particular study and examining whether the results would significantly change.
RESULTS
Fourteen of 128 potential studies on the effects of parenteral lipid emulsions on clinical outcomes met our predefined inclusion criteria (Figure 1) . Four studies compared early with late introduction of lipid emulsions, 9 studies compared different lipid emulsions, and one study compared both. Reasons for exclusion are outlined in Figure 1 .
Early compared with late introduction of lipids
Characteristics of the included studies assessing the effect of early introduction of lipids are shown in Table 1 . In 3 studies, infants included weighed ,1500 g; in the other studies, inclusion was on the basis of gestational age, rather than birth weight (24), or was not specified (25) . Lipid emulsions were initiated between 12 h and 2 d after birth in the intervention groups and between day 5 and day 8 in the control groups. In the studies of Brownlee et al (24) , Gilbertson et al (26) , and Gunn et al (25) , the randomization method was not described or was inappropriate. None of the studies were blinded, and followup was described in all studies. Baseline characteristics and outcome measures of the studies are shown in Table 2 . In these 5 studies, a total of 456 infants were included: 233 in the intervention groups and 223 in the control groups. Sosenko et al (27) performed separate analyses for infants with birth weights of 600-800 g and 801-1000 g; therefore, we considered the results of each weight category as a separate study.
Outcome measures
Three of 5 studies only reported that growth was no different between treatment groups, rather than specifying exact growth rates. Brownlee et al (24) reported mean weight gain during hospital admission (not significantly different between groups), and Gilbertson et al (26) presented growth only during the first week of life instead of during total hospital admission (more weight loss in the intervention group; days to regain birth weight did not differ between groups). Because of a lack of consistency in this outcome measure, a meta-analysis of weight gain during hospital admission was not possible. However, the individual study results suggested that earlier initiation of lipid emulsions does not have an effect on growth rates during the total hospital stay. This finding was further supported by the equal number of days to regain birth weight in both treatment groups (on the basis of 2 studies; mean difference: 0.20; 95% CI: 23.11, 3.51; P = 0.91; n = 60) ( Figure 2A) .
Death during the first 28 d was reported in 2 studies and involved 162 infants. Sosenko et al (27) reported that mortality of infants weighing 600-800 g was higher in the early-lipid group, whereas it was no different in the total population (600-1000 g) or in the study by Gilbertson et al (26) . A meta-analysis of these studies did not show a significant effect of early introduction of lipids on mortality during the first 28 d. The heterogeneity of these studies was shown by an I 2 of 56%. Sensitivity analysis with removal of the 600-800-g subgroup and combined analyses of the 600-1000 g in Sosenko et al (27) did not change the results of the meta-analysis. All 5 studies reported death during the total hospital stay. Individual studies did not find significant differences in overall mortality, except in the 600-800-g birth weight group in the Sosenko et al study (27) . Meta-analysis did not show significant effects of early lipid administration on mortality during hospital stay.
The incidence of BPD [or chronic lung disease (CLD)] was reported in 4 studies. Brownlee et al (24) reported the diagnosis of CLD on the basis of 28 d of oxygen dependence. In Gilbertson et al (26), Sosenko et al (27) , and Wilson et al (28) , BPD/CLD was based on history plus radiology appearance in infants who required supplemental oxygen after 28 d of life. Individual study results and meta-analyses of these 3 studies did not show an effect of early lipid introduction on the incidence of BPD/CLD. Only Gilbertson et al (26) reported data on duration of respiratory support and supplemental oxygen in a manner that could be used for meta-analysis. No individual study found significant differences in these outcomes.
The incidence of NEC and sepsis was reported in 4 studies. Gilbertson et al (26) defined septicemia as a positive blood culture or a clinical picture with hematologic evidence indicating infection. Sosenko et al (27) defined sepsis as a positive blood culture result associated with compatible clinical signs. Wilson et al (28) did not specify the diagnosis of sepsis. No significant effect of early lipid introduction was found in individual studies or in our meta-analysis. The incidence of ROP, PDA, and IVH (all grades) was reported in 3 studies. Again, no effect of early lipid introduction was detected in individual studies or in the combined meta-analysis. None of the studies presented data on the incidence of IVH !grade 3, PNALD, or EFA deficiency. Two studies reported the incidence of significant jaundice necessitating phototherapy in a manner that could be used for meta-analysis, and meta-analysis did not show an effect of early introduction of lipids on significant jaundice. Hypertriacylglycerolemia, defined as triacylglycerol concentrations .200 mg/dL (2.3 mmol/L), was not specified in the included studies. However, when the lower threshold of 1.5 mmol/L defined by Gilbertson et al (26) was used, 2 studies could be included in the meta-analysis that did not show manipulation by early lipid introduction. The incidence of hypoglycemia was reported only in the study by Gilbertson et al (26) and was not significantly different between treatment groups. The incidence of hyperglycemia was reported by Gilbertson et al (26) and Wilson et al (28) . Gilbertson defined hyperglycemia as glucose concentrations .8.0 mmol/L (144 mg/dL), and Wilson defined it as glucose concentrations .11.0 mmol/L with glucosuria. A meta-analysis of these 2 studies did MCT, medium-chain triacylglycerol; RCT, randomized controlled trial; TPN, total parenteral nutrition. Quality was assessed by using the Jadad et al (22) criteria (0-5-point rating scale, with 5 as the maximum score). BPD, bronchopulmonary dysplasia; EFA, essential fatty acid; HyperTG, hypertriacylglycerolemia; IVH, intraventricular hemorrhage; ND, no data; NEC, necrotizing enterocolitis; NS, in study described as not different between treatment groups, no data presented; PDA, patent ductus arteriosus; PNALD, parenteral nutrition-associated liver disease; ROP, retinopathy of prematurity.
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Median; range in parentheses. not show an effect of early lipid introduction. None of the included studies presented data on F2-isoprostane concentrations or neurodevelopment. The results of the performed meta-analyses are shown in Figure 2 , B-L.
Sensitivity analysis by removing studies with a Jadad score ,3 (24) (25) (26) and studies in which the lipid intervention was part of a package of more aggressive parenteral and/or enteral nutrition (24, 25, 28) did not significantly change the results. 
Comparison of lipid emulsions
Characteristics of the 10 studies that compared different lipid emulsions are shown in Table 3 . The inclusion of preterm infants was on the basis of gestational age in 3 studies (29-31), of birth weight in 2 studies (28, 32), of both (33-36) or not specified (37) in others. Lipid emulsions with MCT-soybean, olive-soybean, soybean-MCT-fish, or soybean-MCT-olive-fish were compared with pure soybean oil emulsions or with MCT-soybean oil emulsions. In one study, the treatment group received an MCTsoybean emulsion combined with earlier amino acid administration and early minimal feeding (28) . In the studies by Lehner (31) were described as double-blinded. However, the method of double blinding was appropriately described only in the studies by Deshpande et al (29) , Rayyan et al (33) , and Skouroliakou et al (35) . Follow-up was described in all studies. In Table 4 , baseline characteristics and outcome measures of the studies are shown. A total of 499 infants were included: 249 in the intervention groups and 250 in the control groups.
Outcome measures
None of the studies presented the rate of weight gain during the total period of hospital stay. Lima et al (37) and Tomsits et al (31) presented the rate of weight gain during the first 2 wk, which was no different between groups. Rayyan et al (33) presented the rate of weight gain during the study period (days 7-14), which was no different between groups. Three other studies (29, 30, 32) mentioned only that the rate of weight gain during hospital admission was not different between treatment groups, rather than specifying growth rates. Four studies presented only weight at day 8 (34) or day 14 (36) or the final weight (28, 35) instead of growth rate. Meta-analysis of the studies by Lima et al (37) (MCT-soybean oil), Rayyan et al (33) (soybean-MCT-olive-fish), and Tomsits et al (31) (soybean-MCT-olive-fish) did not show a significant effect of lipid emulsion on growth rate during the first 2 wk of life (weighted mean difference: 0.07; 95% CI: 22.46, 2.59; P = 0.96; n = 158) ( Figure 3A) .
Of the secondary outcomes, meta-analyses could be performed for the following variables: death before discharge, duration of respiratory support, and the incidence of sepsis, hypertriacylglycerolemia, and hyperglycemia. Hypertriacylglycerolemia was defined as a triacylglycerol concentration .1.9-3.4 mmol/L (28, 33, 36) or not specified (34) . Hyperglycemia was defined as glucose concentration .8 mmol/L (37), .11 mmol/L (35), or .11 mmol/L plus glucosuria (28) . Lipid sources that were not purely soybean based caused a 25% reduction in sepsis episodes (RR: 0.75; 95% CI: 0.56, 1.00; P = 0.05; 3 studies, n = 197). Other outcomes were not affected by the type of lipid emulsion. The results of the performed meta-analyses are shown in Figure 3 , B-F. Sensitivity analysis performed by removing studies with a Jidad score ,3 (30, 31, 34, 36) , studies in which the lipid intervention was part of a package of more aggressive parenteral and/or enteral nutrition (28) , or studies in which the lipid intervention was after the first few days of life (33) did not change the results significantly, except for the outcome of sepsis. When GA, gestational age; MCT, medium-chain triacylglycerol; RCT, randomized controlled trial. Quality was assessed by using the Jadad et al (22) criteria (0-5-point rating scale, with 5 as the maximum score). BPD, bronchopulmonary dysplasia; EFA, essential fatty acid; HyperTG, hypertriacylglycerolemia; IVH, intraventricular hemorrhage; ND, no data; NEC, necrotizing enterocolitis; NS, in study described as not different between treatment groups, no data presented; PDA, patent ductus arteriosus; PNALD, parenteral nutrition-associated liver disease; ROP, retinopathy of prematurity. (28) were removed from this analysis, the type of lipid emulsion did not make a significant difference in the incidence of sepsis.
DISCUSSION
In this systematic review, the benefits and adverse effects of lipid introduction within the first 2 d of life and the effects of the type of lipid were reported. The meta-analysis of lipid introduction within the first 2 d of life was based on 5 studies in 456 preterm infants. The results of this meta-analysis suggest that the initiation of lipids within the first 2 d of life is well tolerated, does not offer significant benefits on growth, and does not cause a higher incidence of adverse events. For the primary outcome, growth during hospital admission, the reporting of results was too inconsistent to perform a meta-analysis. However, results of individual studies suggested no effect from the initiation of lipids before or after day 2 of life on growth during hospital admission. The time required to regain birth weight was also not significantly different between treatment groups. The difference of 2 d when lipids are introduced is probably too small an interval to result in persistent differences in growth. This finding was supported by a previous meta-analysis of 5 RCTs performed by Simmer and Rao (8) , which reported that a 5-d difference in the initiation of lipids did not result in growth benefits in the early-lipid group (8) . In addition to the studies by Brownlee et al (24) , Gilbertson et al (26) , and Sosenko et al (27) , which were included in our metaanalysis, Simmer et al also included Alwaidh et al (38) and Hammerman et al (39) . We excluded these latter 2 studies (38, 39) because lipids were initiated after day 2 in both treatment groups.
A meta-analysis of the effects on the secondary outcomes death and incidence of BPD, NEC, ROP, PDA, sepsis, IVH, significant jaundice, hypertriacylglycerolemia, or hyperglycemia did not show significant differences between initiation of lipids before or at day 2 compared with after day 2. For the secondary outcomes of duration of respiratory support and supplemental oxygen, the incidence of PNALD, EFA deficiency, hypoglycemia, signs of lipid peroxidation, and long-term neurodevelopmental outcome, no meta-analysis could be performed because of insufficient data. One of the included studies in the meta-analysis [ie, Sosenko et al (27) ] reported higher mortality in the subgroup of infants with a birth weight of 600-800 g. However, this study has been criticized on methodologic grounds because the subgroup analysis was post hoc, antenatal corticosteroid use was significantly lower in the early-lipid group, and initial illness severity was not recorded (28) . The results of our meta-analysis were in agreement with the meta-analysis of Simmer et al (5-d difference in the initiation of lipids) (8) . The absence of an effect on BPD and mortality was also in agreement with the meta-analyses of Fox et al (40) and Wilson et al (41) , both of which were published in abstract form only.
A limitation of all included studies is that the amino acid intake was rather low or even absent during the first few days compared with current recommendations (42) , resulting in general undernutrition of the studied preterm infants. Several studies suggest that the initiation of lipids in combination with an adequate amount of amino acids may make a difference in growth. However, these studies were excluded from this systematic review for reasons explained below. The study by Ibrahim et al (43) was excluded because no growth outcomes were reported. However, the researchers reported a higher nitrogen balance, as a proxy of lean tissue growth, without increased incidence of metabolic or respiratory complications with introduction of high doses of amino acids (3.5 g Á kg
) within the first 2 h of life compared with 48 h after birth. The RCTs by Drenckpohl et al (44) and Tan and Cooke (45) were excluded because lipids were initiated at or before day 2 in both treatment groups. Drenckpohl et al (44) showed that introduction of 2.0 g Á kg 21 Á d 21 compared with 0.5 g Á kg 21 Á d 21 of purely soybean oil-based lipid infusion in combination with 3 g amino acids Á kg 21 Á d 21 on day 1 to VLBW infants (n = 48 and 52, respectively) improved energy intake, decreased weight loss, allowed an earlier regain of birth weight, and decreased incidence rates of NEC (although the incidence in the control group was higher than their annual average) and ROP, whereas the incidence of other common morbidities, such as BPD, was unchanged. Hypertriacylglycerolemia was observed more frequently in the higher-lipid group (15% compared with 4% of infants), which was as expected. In the study by Tan et al (45) , hyperalimentation (20% more dextrose, protein, and fat starting at day 1; n = 68) compared with standard nutrition (n = 74) resulted in a reduction of postnatal growth failure without adverse clinical effects. RCTs on the effect of lipids on long-term development are lacking. However, cohort studies suggest developmental advantages with early introduction of lipids and/or a higher energy intake (46) (47) (48) . In the cohort study of Eleni Dit Trolli et al (47) and Stephens et al (48) , a higher energy (and lipid) intake in the first weeks was associated with a higher developmental outcome at 1 y corrected age and higher Mental Development Index scores and lower likelihood of length growth restrictions at 18 mo corrected age, respectively. In addition, Ehrenkranz et al (46) showed that the total daily energy intake during the first week of life in extremely low-birth-weight infants was associated with decreased early morbidity. Therefore, the lack of differences in growth and morbidities with early introduction of lipids as shown by this meta-analysis should not exclude the use of lipids within the first few days of life in VLBW infants.
In addition to the effect of earlier initiation of lipids, the effects of the type of lipid emulsion on growth and adverse outcomes in 499 preterm infants from 10 studies were reported in the present systematic review and meta-analysis. No statistically significant differences were observed for the primary outcome (growth during hospital admission) or during the first weeks of life on the basis of the type of lipid emulsion used. The type of lipid also did not affect the secondary outcomes of death, incidence of BPD, duration of respiratory support and supplemental oxygen, incidence of NEC, hypertriacylglycerolemia, and hyperglycemia. The included studies did not report data on the following outcomes: incidence of ROP, PDA, IVH, jaundice, PNALD, EFA deficiency, or hypoglycemia; signs of lipid peroxidation; or longterm neurodevelopmental outcome. This review shows that lipid emulsions that are not purely soybean based (eg, MCT-soybean, olive-soybean, and soybean-MCT-olive-fish emulsions; Table 5 ) are weakly associated with fewer episodes of sepsis than pure soybean oil emulsions (RR: 0.75; 95% CI: 0.56, 1.00; based on 2 studies). This finding might be explained by the lower amount of n26 fatty acids, because an excess intake of n26 PUFAs may result in increased synthesis of proinflammatory eicosanoids (50) (51) (52) . In addition, the n23 fatty acids in fish oil may reduce Data were provided by the manufacturers and adapted from Wanten et al (49) . MCT, medium-chain triacylglycerol; NP, not provided.
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inflammatory responses while protecting immunity (52) . However, more adequately powered RCTs are necessary to confirm the effect of type of lipid emulsion on the prevention and possible treatment of sepsis episodes. A general limitation of this systematic review is that studies were excluded when growth data were not presented. We used growth as our primary outcome because the ultimate goal of nutritional intervention is to support normal growth and development (ie, comparable to term-born infants) without increasing the incidence of adverse events. A second limitation is that outcome measures were defined inconsistently in the studies, which made it necessary to adjust our predefined criteria of certain outcomes, such as hypertriacylglycerolemia and hyperglycemia. However, because both individual studies and our meta-analysis found no differences between treatment groups for these outcomes, we believe that the adjustments did not change the results. Another limitation is that we could not perform separate meta-analyses for the different lipid emulsions because insufficient data were available per outcome and per type of emulsion.
In summary, available data show that lipid administration within the first 2 d of life to preterm infants seems safe and well tolerated; however, beneficial effects on growth were not observed. Despite the lack of growth benefits, the use of lipids within the first few days of life in VLBW infants should not be withheld. Further well-designed and adequately powered studies are necessary to determine the effects of early lipid administration with or without a higher amino acid intake on neurodevelopmental outcome.
The use of lipid emulsions that are not purely soybean-based in preterm infants may result in a lower incidence of sepsis, whereas other adverse events were not affected by type of lipid. The type of lipid emulsion did not make a difference in the growth of preterm infants during hospital stays. Future large-scale RCTs in preterm infants are thus warranted to show whether these lipid emulsions result in improved long-term outcomes.
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